Huntington, NY, United States of America

Albert S Mellick

This inventor holds 1 USPTO granted patent. Top assignee: Cold Spring Harbor Laboratory. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Albert S Mellick. Retrieved from https://idiyas.com/inventor/albert-s-mellick

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Albert S. Mellick: Inventor in Tumor Treatment

Introduction

Albert S. Mellick is an inventor associated with Cold Spring Harbor Laboratory in Huntington, New York. His work includes an invention focused on treating tumors by targeting bone marrow-derived endothelial progenitor cells.

Latest Patents

Mellick is credited with 1 patent: “Treatment of Tumors by Ablating Bone Marrow-Derived Endothelial Progenitor Cells.” The invention describes methods for treating tumors and other conditions characterized by abnormal neoangiogenesis by inhibiting these cells.

Career Highlights

Mellick’s patent reflects research into the role of endothelial progenitor cells in abnormal blood-vessel formation and tumor growth. The disclosed approach aims to address neoangiogenesis by inhibiting cells derived from bone marrow.

Collaborations

Mellick’s listed coworkers include Vivek Mittal and Dingcheng Gao. Their shared association with Cold Spring Harbor Laboratory connects the invention to the institution’s research environment.

Conclusion

Albert S. Mellick’s patent documents an approach to tumor treatment that targets bone marrow-derived endothelial progenitor cells involved in abnormal neoangiogenesis.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…